Hemogenyx Pharmaceuticals plc (HEMO.L) Diversifiers

Equity · Currency in GBp · Last updated Jun 6, 2026

Hemogenyx Pharmaceuticals plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Looking to balance out your exposure to HEMO.L? The ETFs below have the lowest correlation with HEMO.L — they tend to move on their own, which can help reduce risk when HEMO.L drops. The stock ideas table highlights individual companies that behave independently from HEMO.L.

No Diversifiers Found for HEMO.L

We do not have enough correlation history to rank diversifiers for this symbol yet.

Diversification Analysis

Build a portfolio that complements HEMO.L

Add HEMO.L to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with HEMO.L